Volume 16, 2 Issues, 2020 ISSN: 1875-631X (Online) ISSN: 1573-3955 (Print)
This journal supports open access
By signing the Copyright Letter, the authors retain the rights of self-archiving (subject to certain restrictions).
Following are the important features of the self-archiving policy of Bentham Science journals:
Authors can deposit the first draft of a submitted article on their personal websites or their institution’s repositories for personal use, internal institutional use, or for permitted scholarly posting only.
Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution’s repository or the non-commercial repositories, PMC and arXiv, after 12 MONTHS of publication on the journal website. For personal use, internal institutional use, or for permitted scholarly posting only.
In case of (b) above, an acknowledgement must be given to the original source of publication and a link must be inserted to the published article on the journal's/publisher’s website. The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/[insert DOI].”
If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published versions of manuscripts in the nominated institutional repositories, after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts unless under an Open Access mandate as above. Archiving, under any of the above mentioned Open Access mandates, is done under the terms of the Creative Commons License CC BY-NC-ND 4.0 - Attribution-NonCommercial-NoDerivatives 4.0 International.
There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website. This is done under the terms of the Creative Commons Attribution 4.0 International Public License CC-BY 4.0.
In case of any form of archiving, an acknowledgement must be given to the original source of publication and a link must be inserted to the published article on the journal's/publisher’s website. The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: “The published manuscript is available at EurekaSelect via http://www.eurekaselect.com/[insert DOI].”
LONG-TERM ARCHIVING OF BENTHAM SCIENCE CONTENT
To ensure permanent access to our publications, Bentham Science has an agreement with Portico to have a long-term preservation of the content published in its journals.
Cecil Czerkinsky Institut de Pharmacologie Moleculaire et Cellulaire UMR 7275 CNRS-INSERM-UNISA 660 Route des Lucioles Valbonne, 06560 (France) Biography
Biography of Cecil Czerkinsky
Dr. Czerkinsky is currently Research Director at the Institute of Molecular and Cellular Pharmacology, a research organization spearheaded by the French National Research Council (CNRS), the National Institute of Health and Medical Research (INSERM) and the University of Nice at Sophia Antipolis (France). He previously served as Deputy Director General and Head of R&D at the International Vaccine Institute (Seoul, South Korea) and as Professor at Seoul National University, Korea University, and Göteborg University (Sweden). He has authored more than 180 scientific publications and is an inventor of more than 20 patents in the field of immunology and vaccine science.